Future Prospects for Regenerated Heart Using Induced Pluripotent Stem Cells

Access this Article

Author(s)

Abstract

Induced pluripotent stem cell (iPSC) generation is an epoch-making technology. The potential applications for iPSCs are wide-ranging from in vitro disease models to drug discovery. For regenerative medicine in particular, the technology provides great hope for patients with incurable diseases or potentially fatal disorders such as heart failure (HF). However, the true realization of that promise for HF remains uncertain and moving toward the clinical application of iPSCs needs to be stepwise and careful. The establishment of "safe" iPSCs must be a major premise, while genome integration-free and oncogene-free reprogramming is also necessary. Teratoma formation also remains a risk with undifferentiated iPSCs, but it must not happen in patients' bodies. Thus, regardless of the target organ, the differentiated cells from iPSCs must be purified to exclude any possibility of tumorigenicity. The transplantation strategies used for iPSC-derived cells are very important for the recovery of lost cardiac function. Longer engraftment of transplanted iPSCs-derived cardiomyocytes is essential particularly because their survival could be hampered by ischemia, inflammation, apoptosis, immunological rejection, and other cardiac phenomena. Providing these multistep solutions will open the new frontier of regenerative therapies with iPSCs for patients with severe HF.

Journal

  • Journal of Pharmacological Sciences

    Journal of Pharmacological Sciences 125(1), 1-5, 2014

    The Japanese Pharmacological Society

Codes

  • NII Article ID (NAID)
    130003391517
  • NII NACSIS-CAT ID (NCID)
    AA11806667
  • Text Lang
    ENG
  • ISSN
    1347-8613
  • NDL Article ID
    025463062
  • NDL Call No.
    Z53-D199
  • Data Source
    NDL  J-STAGE 
Page Top